BridgeBio Oncology Therapeutics
BBOT
Positions held
Your positionsBBOT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $274.20M | Enterprise value | $51.00M | Trailing P/E | — | Forward P/E | -1.26 |
| PEG | — | Price / book | 0.85 | Beta | 0.65 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -81.9% | ROA | -47.1% | Debt / equity | 0.01 |
| Current ratio | 4.69 | Free cash flow | -$89.98M | Analyst recommendation | none | Mean target | $24.55 |
| 52w high | $14.87 | 52w low | $3.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$56.5M | -$42.1M | -$38.8M | -$44.8M | -$28.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.2M | -$46.2M | -$43.4M | -$49.2M | -$30.1M |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$134M | -$74.3M | -$64.7M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$146M | -$80.9M | -$64.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-12 · BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
2026-09-11 · Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-08 · BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results
2026-09-01 · BBOT to Participate in Upcoming Investor Healthcare Conferences
2026-08-11 · BridgeBio Oncology Q2 Loss Widens
2026-08-11 · BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 · BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Price (daily)
Full chart · RSI · MACD · patterns